Fig. 6: Metabolic characterization of ATO-resistant NB4 cells (ATOR #2 and #4 clones) and control cells. | Leukemia

Fig. 6: Metabolic characterization of ATO-resistant NB4 cells (ATOR #2 and #4 clones) and control cells.

From: PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias

Fig. 6

A glycolytic and mitochondrial ATP production rate using the XF Real-Time ATP Rate Assay. Data represent two independent biological replicates performed in MT and PR9 (PML::RARα+) cells. B BODIPY staining. Representative images (20x magnification) of (up) NB4 Ctrl #2 vs. ATOR #2 and (down) in NB4 Ctrl #4 vs. ATOR #4, stained with BODIPY 493/503 (D-3922). Scale bar 10 μm. C Two-dimension (2D) and (3D) synergy map for the combination of SSO (CD36 inhibitor) (0 to 100 µM) and ATO (0 to 1 µM) analyzing cell growth by MTT assay. Data represent two independent biological replicates performed in MT and PR9 (PML::RARα+) cells. The ZIP score (∂-score) for each drug combination is indicated by the color code given above the panel grid (synergistic and antagonistic dose regions in red and green colors, respectively). ZIP score >10 indicates synergism; ZIP score between -10 and 10 indicates additivity; and ZIP score <-10 indicates antagonism. Panels A and B and C were obtained by Synergy Finder analysis (https://synergyfinder.fimm.fi/synergy/synfin_docs/).

Back to article page